ASX:RAP

ResApp Health Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume932,978 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive RAP News and Ratings via Email

Sign-up to receive the latest news and ratings for ResApp Health and its competitors with MarketBeat's FREE daily newsletter.


About ResApp Health

ResApp Health Limited develops digital healthcare solutions to assist doctors and allow patients to diagnose and manage respiratory disease. The company offers ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department, and primary care markets; and SleepCheck, a direct-to-consumer smartphone application for the self-assessment of sleep apnoea in 36 countries. Its technology uses sound to diagnose respiratory diseases, including pneumonia, bronchiolitis, bronchitis, chronic obstructive pulmonary disease, and asthma. ResApp Health Limited has a joint development and pilot agreement with Medgate AG to integrate and test smartphone-based acute respiratory diagnostic test. The company was formerly known as Narhex Life Sciences Limited. ResApp Health Limited was founded in 2014 and is headquartered in Brisbane, Australia.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.72 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











ResApp Health (ASX:RAP) Frequently Asked Questions

What stocks does MarketBeat like better than ResApp Health?

Wall Street analysts have given ResApp Health a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ResApp Health wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is ResApp Health's next earnings date?

ResApp Health is scheduled to release its next quarterly earnings announcement on Monday, August 30th 2021.
View our earnings forecast for ResApp Health
.

Who are ResApp Health's key executives?

ResApp Health's management team includes the following people:
  • Dr. Anthony Keating, CEO, MD & Director
  • Al Rey Lunar CPA, VP of Fin.
  • Ms. Nicki Farley, Company Sec. (Age 45)
  • Dr. Clas Källander, Founder and Director of R&D of Cavidi AB
  • Mr. Brian Leedman BECON, M.B.A., B.Econ., VP of Corp. Affairs
  • Dr. Paul Porter, Scientific Advisor

Who are some of ResApp Health's key competitors?

What is ResApp Health's stock symbol?

ResApp Health trades on the ASX under the ticker symbol "RAP."

How much money does ResApp Health make?

ResApp Health has a market capitalization of $0.00 and generates $46,197.00 in revenue each year.

How many employees does ResApp Health have?

ResApp Health employs 500 workers across the globe.

What is ResApp Health's official website?

The official website for ResApp Health is www.resapphealth.com.au.

How can I contact ResApp Health?

The company can be reached via phone at 61 7 3724 0035.


This page was last updated on 7/30/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.